GA, UNITED STATES, February 4, 2026 / EINPresswire.com / — Researchers have developed a new biomimetic nanocomposite ...
Phase 3 clinical trial results demonstrate that Ameluz photodynamic therapy is an effective treatment for actinic keratoses ...
WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...
The FDA accepted the supplemental new drug application (sNDA) for aminolevulinic acid hydrochloride 10% topical gel (Ameluz) as part of photodynamic therapy (PDT) for superficial basal cell carcinoma ...
US FDA acknowledges no filing deficiencies in Biofrontera’s sNDA for Ameluz PDT in superficial basal cell carcinoma: Woburn, Massachusetts Saturday, February 14, 2026, 16:00 Hrs ...
Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel ...
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first ...
Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced ...
Chronic infected wounds can take over daily life, especially for people living with diabetes. These wounds often refuse to ...
The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.
The comparative efficacy of surgical excision, 5-fluorouracil, and methylaminolevulinate photodynamic therapy for the treatment of Bowen disease was examined.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results